Recently, a thesis from the department of breast surgery of Shanghai Renji Hospital was referred by 2015 American NCCN guideline for the treatment of breast cancer. The study (“For or against Adjuvant Trastuzumab for Breast Cancer Patients with HER2-Positive Tumors: A Meta-Analysis of Published Literatures”) was carried out by Professor Lu Jinsong’s team. This is by far the first time for NCCN clinical guideline to cite a research work from China, which demonstrated that the clinical and scientific level of our breast disease clinical center have gradually entered the world’s leading rank.

The American NCCN guideline for breast cancer is one of the most important programmatic document guiding the international clinical practice of the disease diagnosis and treatment. As the basis and direction of standardized and individualized treatment, it enjoys great attention and trust among clinicians. The development of these guidelines and consensus is based on the views and perspectives extracted from important global clinical trials. Being cited by this international guideline affirms the potential general guidance and reference value of the study in current treatment of breast cancer. The thesis of Lu Jinsong’s team conducted in-depth clinical exploration and theoretical research in the academic significance of small breast tumors as well as its prognosis and the possible significance of targeted therapies, which has a relatively high value for references. NCCN’s current citation not only indicates that the clinical and academic thinking of our breast disease center is of good practicality and advancement, but also represents that the research work and voice from Chinese clinicians and scientists begin to be heard on the stage of international clinical guidelines with a tight integration with the world academic frontier.

Correspondent Xu Shuguang , Translator Sun yujun